is semaglutide on the fda shortage list ends as sets deadline for compounders fda compounded semaglutide decision US

While the medication itself does not require tapering from a pharmacological standpoint, the clinical context surrounding discontinuationparticularly the management of underlying conditions like diabetes or obesitydemands careful planning and medical supervision to ensure patient safety and optimize long-term health outcomes

Talking with your doctor about these side effects can help them adjust your treatment if needed

HH: Data curation, Investigation, Methodology, Validation, Writing review & editing

Protocol duration depends on individual response and injury characteristics

If you look across the randomized trials, the adverse event rates to me are fairly alarming